Clinical Trial Update: Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus [Phase 3]

View source ↗

Summary

A Phase 3 study of alvimopan for managing opioid-induced postoperative bowel dysfunction and postoperative ileus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Bowel Dysfunction
• Postoperative Ileus

Drugs mentioned

• Entereg (alvimopan)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Ileus | Phase 3 | Status: COMPLETED